Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.

Clinical advances in hematology & oncology : H&O - 1 Jul 2018

Sulai Nanna H, Tan Antoinette R

Abstract excerpt

The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA. The use of PARP inhibitors is a rational therapeutic approach to selectively killing a subset of cancer cells with deficiencies in DNA repair pathways. PARP inhibitors that have undergone clinical investigation in the treatment of breast cancer include olaparib, talazoparib, veliparib,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 30067621

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.PMID 30067621Read ↗

PARP inhibitors in the management of breast cancer: current data and future prospects.Semantic proximity Read ↗

An Overview of PARP Inhibitors for the Treatment of Breast CancerSemantic proximity Read ↗

Advances in PARP inhibitors for the treatment of breast cancer.Semantic proximity Read ↗

Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: TalazoparibSemantic proximity Read ↗

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.Semantic proximity Read ↗

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer TreatmentSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?Semantic proximity Read ↗

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer TreatmentSemantic proximity Read ↗

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?Semantic proximity Read ↗

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future PerspectivesSemantic proximity Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.